BUSINESS OBJECTIVES AND STRATEGIES

Our Group intends to pursue the expansion of its business operations by implementing the business strategies as set out below. For further details of our business strategies, please refer to the paragraph headed "Business — Business Strategies" in this document.

Our Group's actual course of business may vary from the business objectives as set out in this document. There can be no assurance that the plans of our Group will materialise in accordance with the expected timeframe or that the business objectives of our Group will be achieved at all.

REASONS FOR THE [REDACTED] AND THE [REDACTED]

The principal business objective of our Group is to further strengthen our market position, increase our market share and capture the growth opportunities in the personal protective and healthcare products markets in Hong Kong.

Our Directors believe that the **[REDACTED]** is beneficial to our Company and our Shareholders as a whole for the following reasons:

- the **[REDACTED]** from the **[REDACTED]** will provide additional financial resources to our Group for our business plans as set out in the paragraph headed "Business — Business strategies" in this document, which will further strengthen our market position and enable us to capture the future opportunities arising from the growth of the healthcare products industry in Hong Kong;

- a public **[REDACTED]** status will enhance our corporate profile and recognition and enable our Group to be considered more favourably by our customers when competing for or securing manufacturing contracts and orders for our healthcare products, given that a **[REDACTED]** company is subject to ongoing regulatory compliance for announcements, financial disclosures and corporate governance;

- the **[REDACTED]** will provide a fund-raising platform for our Company, thereby enabling us to raise the capital required to finance our future growth and expansion plans without reliance on our Controlling Shareholders. This platform will allow us to gain direct access to the capital market for equity and/or debt financing, both at the time of the **[REDACTED]** and in the future, to fund our existing operations as well as our expansion into local and overseas markets. Such access to capital is expected to be instrumental to our business expansion, improve our operating and financial performance, and ultimately enhance returns to our Shareholders; and

- Upon the **[REDACTED]**, our Shares will be freely traded on the GEM. A public listing status will provide us with a broader shareholder base, which could in turn lead to a more liquid market for the trading of our Shares.

[REDACTED]

We estimate that the **[REDACTED]** from the **[REDACTED]** (assuming the **[REDACTED]** is not exercised) based on the **[REDACTED]** of HK$**[REDACTED]** per **[REDACTED]**, being the mid-point of the indicative **[REDACTED]** range of HK$**[REDACTED]** to HK$**[REDACTED]** per **[REDACTED]**, after deducting the related **[REDACTED]**, are estimated to be approximately HK$**[REDACTED]** million. We intend to apply such **[REDACTED]** in the following manner:

Strengthening R&D capabilities and expanding our product pipeline

(a) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]** of the estimated **[REDACTED]**, will be used for research and development, of which (i) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]**% of the estimated **[REDACTED]**, will be used for refining our existing wheelchair projects; (ii) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]**% of the estimated **[REDACTED]**, will be used for developing three new projects (namely foldable cane chair, SAP material related personal care products and electronic healthcare products with smart system); and (iii) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]**% of the estimated **[REDACTED]**, will be used for acquiring the required R&D equipment.

Our Directors believe that continued investment in R&D is essential to refining our existing projects and product lines, developing new projects, expanding our product pipeline, and procuring the necessary supporting equipment. In this regard, our R&D strategy will continue to align with broader industry trends, including cross-category expansion, digital transformation, the intelligent and portable transformation of medical products, to address the growing demand for healthcare and wellness products. We may also explore the development of high-performance SAP base formulations where appropriate. In particular, we intend progressively to adopt the USB-C universal interface across our applicable medical products and integrate intelligent functionalities, in order to improve user convenience, enhancing charging compatibility and align with product modernization trends, and support compliance with applicable requirements in overseas markets. We will also explore opportunities to develop products in categories adjacent to our existing business where such opportunities are consistent with our business strategy, technical capabilities and market positioning. In addition, we will continue to monitor changes in customer preferences and developments in the relevant markets in order to support the refinement of our product offering.

Expanding product capacity and manufacturing capabilities

(b) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]** of the estimated **[REDACTED]**, will be used for investment in our production facility to improve our operational efficiency and strengthen our manufacturing capabilities, including capacity expansion, equipment investment and selected production arrangements to support expansion of our wound care products, and GMP-standard certified facility and other capabilities not currently available in Hong Kong.

Our Directors believe that further investment in our production facility is important to improving our operational efficiency and strengthening our manufacturing capabilities. Currently, our wound care products are in the prototyping and trial production stage at our Tsuen Wan facility in Hong Kong. The proposed investment includes capacity expansion, equipment investment and selected production arrangements to support the mass production of our wound care products, as well as exploring access to GMP-standard production facilities, whether in Hong Kong or overseas, to support product commercialisation.

Deepening downstream market presence and expansion of sales channels

(c) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]** of the estimated **[REDACTED]**, will be used for sales and operation capabilities, including expansion into downstream expansion and overseas marketing to strengthen our market presence. In particular, we intend to pursue selective downstream expansion opportunities, including acquisitions or other means of strengthening our downstream channels.

Our Directors believe that the **[REDACTED]** will provide additional financial resources to strengthen our sales and operations capabilities and deepen our downstream market presence. In particular, we intend to pursue selective downstream expansion opportunities, including acquisitions or other means of strengthening our downstream channels. In evaluating potential acquisition or investment targets, we intend to focus principally on businesses with established institutional sales channels, including hospitals, clinics and elderly care institutions, and which are capable of supporting our downstream expansion and broader product commercialisation strategy. We may also seek to enhance our production processes and quality control capabilities through selected automation and other manufacturing technologies to further improve our efficiency, consistency and operational flexibility.

Recruitment of additional personnel and market development

(d) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]** of the estimated **[REDACTED]**, will be used to recruit additional personnel to support our business expansion, including in areas such as production, sales and operations, exhibition participation, overseas market development and other overseas market initiatives, quality assurance, certification and compliance, and other supporting functions.

Our Directors believe that the continued growth of our business will require additional personnel across a range of functions, including R&D, production, sales and operations, quality assurance, certification and compliance, and other supporting functions. The **[REDACTED]** from the **[REDACTED]** will also support exhibition participation, overseas market development and other overseas market initiatives in Hong Kong and selected overseas markets.

Enhancing our financial flexibility and supporting general working capital needs

(e) approximately HK$**[REDACTED]**, representing approximately **[REDACTED]** of the estimated **[REDACTED]**, will be used for our general working capital.

Our Directors believe that the **[REDACTED]** will broaden our shareholder and capital base, provide a fund-raising platform for future growth and expansion, and strengthen our financial flexibility. Part of the **[REDACTED]** will be applied towards our general working capital, which will support our day-to-day operations and facilitate the implementation of our business strategies.

IMPLEMENTATION PLANS

In order to achieve the business objectives and strategies set out above, our implementation plans are set out below, commencing from the **[REDACTED]** to 31 March 2029. These implementation plans are formulated based on the assumptions set out in the paragraph headed "Basis and assumptions" in this section and are subject to various uncertainties, variables and unforeseen factors. There can be no assurance that the implementation plans will materialise in accordance with the timetable set out below or that our business objectives will be achieved at all.

For the period from the [REDACTED] to 31 March 2027

Business strategies	Implementation plans	[REDACTED]
1. Strengthening R&D capabilities and expanding our product pipeline	• Lease and expand our R&D office • Recruit the initial research and development team for the expanded R&D office, comprising one head of the research and development team, one senior engineer and two junior engineers • Commence procurement of R&D testing, production equipment (including scanning and imaging equipment) and R&D software	**[REDACTED]** of approximately HK$**[REDACTED]**
2. Deepening downstream market presence and expansion of sales channels	• Identify and evaluate potential channel-led medical device distributors and retailers; conduct due diligence • Complete selective acquisition(s)/investment(s) where suitable targets are identified, with target selection focusing on businesses that maintain both institutional distribution capabilities and direct consumer-facing retail and online sales channels.	**[REDACTED]** of approximately HK$**[REDACTED]**
3. Recruitment of additional personnel and market development	• Recruit initial sales and sales-support personnel for the Hong Kong and overseas markets, comprising one Hong Kong sales staff, one overseas sales staff and one sales-support staff • Participate in two exhibitions (one in Hong Kong and one overseas) • Commence marketing and promotional activities	**[REDACTED]** of approximately HK$**[REDACTED]**
4. General working capital	• Apply towards our general working capital	**[REDACTED]** of approximately HK$**[REDACTED]**

For the six months ending 30 September 2027

Business strategies	Implementation plans	[REDACTED]
1. Strengthening R&D capabilities and expanding our product pipeline	• Continue to expand the R&D team by recruiting one senior engineer and four junior engineers • Procure additional R&D equipment (including modeling equipment) and raw materials for product development	**[REDACTED]** of approximately HK$**[REDACTED]**
2. Expanding product capacity and manufacturing capabilities	• Carry out capacity expansion and equipment investment at our production facility for our wound care products	**[REDACTED]** of approximately HK$**[REDACTED]**
3. Recruitment of additional personnel and market development	• Continue marketing, promotional and overseas-certification activities	**[REDACTED]** of approximately HK$**[REDACTED]**

For the six months ending 31 March 2028

Business strategies	Implementation plans	[REDACTED]
1. Strengthening R&D capabilities and expanding our product pipeline	• Procure additional R&D equipment (including precision measurement equipment)	**[REDACTED]** of approximately HK$**[REDACTED]**
2. Recruitment of additional personnel and market development	• Recruit one Hong Kong sales staff and one overseas sales staff • Participate in two exhibitions (one in Hong Kong and one overseas) • Continue overseas certification and marketing activities	**[REDACTED]** of approximately HK$**[REDACTED]**

For the six months ending 30 September 2028

Business strategies	Implementation plans	[REDACTED]
1. Strengthening R&D capabilities and expanding our product pipeline	• Continue procurement of equipment and materials	**[REDACTED]** of approximately HK$**[REDACTED]**
2. Recruitment of additional personnel and market development	• Continue sales, overseas-certification and marketing activities	**[REDACTED]** of approximately HK$**[REDACTED]**

For the six months ending 31 March 2029

Business strategies	Implementation plans	[REDACTED]
1. Strengthening R&D capabilities and expanding our product pipeline	• Complete the planned R&D team build-out by recruiting one further junior engineer and complete the product development programme • Complete final procurement of equipment and materials	**[REDACTED]** of approximately HK$**[REDACTED]**
2. Recruitment of additional personnel and market development	• Recruit one Hong Kong sales staff and one overseas sales staff • Participate in two exhibitions (one in Hong Kong and one overseas) • Complete the planned market development programme	**[REDACTED]** of approximately HK$**[REDACTED]**

BASIS AND ASSUMPTIONS

The implementation plan set out by our Directors is based on the following assumptions:

- our Group will have sufficient financial resources to meet the planned capital expenditure and business development requirements during the period to which our future plans relate;

- there will be no material changes in the funding requirement for each of our Group's future plans described in this document from the amount as estimated by our Directors;

- there will be no material changes in existing laws and regulations, or other Government policies relating to our Group, or in the political, economic or market conditions in which our Group operates in;

- there will be no changes in the effectiveness of the licences, permits and qualifications obtained by our Group, where applicable;

- there will be no material changes in the bases or rates of taxation applicable to the activities of our Group;
- there will be no disasters, natural, political or otherwise, which would materially disrupt the businesses or operations of our Group; and
- our Group will not be materially affected by the risk factors as set out in the section headed "Risk Factors" in this document.

There can be no assurance that the **[REDACTED]** from the **[REDACTED]** will be sufficient for fully implementing our business expansion plans. In the event any of the above occurs or that the **[REDACTED]** becomes unsuccessful such that the **[REDACTED]** from the **[REDACTED]** become unavailable to us, we may adjust the timing and scale of our business expansion plans and/or seek alternative form of financing.

To the extent that the **[REDACTED]** are not immediately applied to the above purposes and to the extent permitted by the applicable laws and regulations, we will deposit the **[REDACTED]** into short-term interest-bearing accounts at licensed commercial banks and/or other authorised financial institutions (as defined under the SFO or applicable laws or regulations in other jurisdictions).

In the event that the **[REDACTED]** is exercised in full, we estimate that we will receive additional **[REDACTED]** of approximately HK$**[REDACTED]** after deducting the related **[REDACTED]** and assuming an **[REDACTED]** of HK$**[REDACTED]** per Share, being the mid-point of the indicative **[REDACTED]** range of HK$**[REDACTED]** to HK$**[REDACTED]**. In the event that the **[REDACTED]** is set at the low-end of the indicative **[REDACTED]** range and the **[REDACTED]** is exercised in full, our Company will receive additional **[REDACTED]** of approximately HK$**[REDACTED]** after deducting the related **[REDACTED]**. In the event that the **[REDACTED]** is set at the high-end of the indicative **[REDACTED]** range and the **[REDACTED]** is exercised in full, our Company will receive additional **[REDACTED]** of approximately HK$**[REDACTED]** after deducting the related **[REDACTED]**. The allocation of the additional **[REDACTED]** will be used in the same proportion as the original **[REDACTED]**.

Assuming the **[REDACTED]** is not exercised at all, and in the event that the **[REDACTED]** is set at the highest or lowest point of the indicative **[REDACTED]** range, the **[REDACTED]** to be received from the **[REDACTED]** after deducting the related **[REDACTED]** will increase or decrease by approximately HK$**[REDACTED]**, respectively, than the **[REDACTED]** to be received based on the mid-point of the indicative **[REDACTED]** range. In such event, the **[REDACTED]** allocated to the payment of upfront costs for our new projects will increase or decrease accordingly.

We will issue an announcement in the event that there is any material change in the **[REDACTED]** of the **[REDACTED]** as described above.